First generation
(erlotinib, gefitinib)
or second generation
(afatinib, dacomitinib)
NSCLC
(Stage IV)
EGFR mutation
Selecting the optimal sequential strategy
Liquid
biopsies
Rebiopsy
Third generation
Osimertinib